Next Article in Journal
An Appraisal of Life’s Terminal Phases and Euthanasia and the Right to Die
Previous Article in Journal
Lymphangitic Metastasis of Recurrent Renal Cell Carcinoma to the Contralateral Lung Causing Lymphangitic Carcinomatosis and Respiratory Symptoms
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 18
Issue 1
10.3747/co.v18i1.623
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Immune Therapy for Breast Cancer in 2010—Hype or Hope?

by
A. Florescu
1,
E. Amir
1,
N. Bouganim
2 and
Mark Clemons
2,*
1
Division of Medical Oncology and Hematology, Princess Margaret Hospital, and Department of Medicine, University of Toronto, Toronto, ON, Canada
2
Division of Medical Oncology, The Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Box 912, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2011, 18(1), 623; https://doi.org/10.3747/co.v18i1.623
Submission received: 10 November 2010 / Revised: 9 December 2010 / Accepted: 5 January 2011 / Published: 1 February 2011

Abstract

The identification of numerous breast cancer antigens has generated increasing enthusiasm for the application of immune-based therapies in breast malignancies. Although the use of monoclonal antibodies has revolutionized the “targeted therapy” of breast cancer, and the immunomodulatory effects of bisphosphonates continue to be evaluated, few studies to date have demonstrated widespread utility for other forms of immunotherapy. The present review assesses modern research and explores whether the hopes for immunotherapy can overcome the hype.
Keywords: breast cancer; immunotherapy; cancer vaccine; cytokine; monoclonal antibody breast cancer; immunotherapy; cancer vaccine; cytokine; monoclonal antibody

Share and Cite

MDPI and ACS Style

Florescu, A.; Amir, E.; Bouganim, N.; Clemons, M. Immune Therapy for Breast Cancer in 2010—Hype or Hope? Curr. Oncol. 2011, 18, 623. https://doi.org/10.3747/co.v18i1.623

AMA Style

Florescu A, Amir E, Bouganim N, Clemons M. Immune Therapy for Breast Cancer in 2010—Hype or Hope? Current Oncology. 2011; 18(1):623. https://doi.org/10.3747/co.v18i1.623

Chicago/Turabian Style

Florescu, A., E. Amir, N. Bouganim, and Mark Clemons. 2011. "Immune Therapy for Breast Cancer in 2010—Hype or Hope?" Current Oncology 18, no. 1: 623. https://doi.org/10.3747/co.v18i1.623

APA Style

Florescu, A., Amir, E., Bouganim, N., & Clemons, M. (2011). Immune Therapy for Breast Cancer in 2010—Hype or Hope? Current Oncology, 18(1), 623. https://doi.org/10.3747/co.v18i1.623

Article Metrics

Back to TopTop